Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001104659-21-030147
Filing Date
2021-03-01
Accepted
2021-03-01 17:23:59
Documents
2

Document Format Files

Seq Description Document Type Size
1 424B5 tm218271-2_424b5.htm 424B5 798130
2 GRAPHIC lg_nabriva-4c.jpg GRAPHIC 95455
  Complete submission text file 0001104659-21-030147.txt   930812
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-248530 | Film No.: 21699551
SIC: 2834 Pharmaceutical Preparations